Cisplatin and Paclitaxel Treatment for Oesophageal Cancer
Author Information
Author(s): Gaast A van der, Kok T C, Kerkhofs L, Siersema P D, Tilanus H W, Splinter T A W
Primary Institution: University Hospital Rotterdam-Dijkzigt
Hypothesis
Can a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel be safely administered to patients with advanced oesophageal cancer?
Conclusion
The study found that it is possible to increase the dose of paclitaxel to 180 mg m−2 without significant toxicity, and 52% of patients showed a partial or complete response.
Supporting Evidence
- The maximum tolerable dose of paclitaxel was found to be 180 mg m−2.
- 52% of evaluable patients had a partial or complete response to the treatment.
- Cumulative sensory neurotoxicity became the dose-limiting toxicity at higher doses of paclitaxel.
Takeaway
Doctors tested a new way to give cancer medicine to help patients with a type of cancer in their throat, and many patients got better.
Methodology
Patients received a fixed dose of cisplatin and increasing doses of paclitaxel every two weeks to find the maximum tolerable dose.
Limitations
The study was limited to a small sample size and focused on a specific patient population.
Participant Demographics
Patients with advanced oesophageal cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website